Robeco Institutional Asset Management B.V. Buys 544,457 Shares of BioMarin Pharmaceutical Inc. $BMRN

Robeco Institutional Asset Management B.V. raised its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 559.8% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 641,718 shares of the biotechnology company’s stock after purchasing an additional 544,457 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in BioMarin Pharmaceutical were worth $35,275,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of BMRN. V Square Quantitative Management LLC bought a new stake in BioMarin Pharmaceutical in the second quarter valued at approximately $25,000. Farther Finance Advisors LLC lifted its position in BioMarin Pharmaceutical by 95.9% in the first quarter. Farther Finance Advisors LLC now owns 431 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 211 shares during the last quarter. Rise Advisors LLC bought a new stake in BioMarin Pharmaceutical in the first quarter valued at approximately $30,000. Brooklyn Investment Group lifted its position in BioMarin Pharmaceutical by 2,250.0% in the first quarter. Brooklyn Investment Group now owns 564 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 540 shares during the last quarter. Finally, Banque Transatlantique SA bought a new stake in BioMarin Pharmaceutical in the first quarter valued at approximately $71,000. Institutional investors own 98.71% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Raymond James Financial assumed coverage on BioMarin Pharmaceutical in a research note on Wednesday, September 3rd. They set an “outperform” rating and a $85.00 target price on the stock. Weiss Ratings reissued a “sell (d+)” rating on shares of BioMarin Pharmaceutical in a research note on Saturday, September 27th. UBS Group boosted their target price on BioMarin Pharmaceutical from $113.00 to $114.00 and gave the company a “buy” rating in a research note on Tuesday, August 5th. Zacks Research cut BioMarin Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 13th. Finally, Wedbush reissued an “outperform” rating and set a $94.00 target price on shares of BioMarin Pharmaceutical in a research note on Tuesday, August 5th. Thirteen analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $92.95.

BioMarin Pharmaceutical Price Performance

Shares of BMRN stock opened at $55.43 on Friday. The stock has a market cap of $10.64 billion, a price-to-earnings ratio of 16.45, a PEG ratio of 0.71 and a beta of 0.33. The business’s fifty day moving average is $56.77 and its 200 day moving average is $58.78. BioMarin Pharmaceutical Inc. has a twelve month low of $52.47 and a twelve month high of $73.51. The company has a quick ratio of 3.60, a current ratio of 5.56 and a debt-to-equity ratio of 0.10.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.